Patents by Inventor Johannes Bange
Johannes Bange has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10358498Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.Type: GrantFiled: August 11, 2015Date of Patent: July 23, 2019Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company, LimitedInventors: Reimar Abraham, Keisuke Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
-
Publication number: 20170226213Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.Type: ApplicationFiled: August 11, 2015Publication date: August 10, 2017Inventors: Reimar Abraham, Keosile Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
-
Patent number: 9284379Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.Type: GrantFiled: January 18, 2013Date of Patent: March 15, 2016Assignee: U3 Pharma GmbHInventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
-
Patent number: 8394927Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.Type: GrantFiled: November 2, 2007Date of Patent: March 12, 2013Assignee: U3 Pharma GmbHInventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
-
Patent number: 8043806Abstract: The invention provides method of diagnosing a receptor tyrosine kinase (RTK)-hyperfunction-induced disorder or a genetic predisposition therefor in a mammal. The method comprises determining the presence of a nucleic acid encoding a mutated fibroblast growth factor receptor-4 (FGFR-4) protein in a nucleic acid sample from a mammal. The presence of a nucleic acid encoding a mutated FGFR-4 protein is indicative of an RTK-hyperfunction-induced disorder or a genetic predisposition therefor.Type: GrantFiled: January 19, 2010Date of Patent: October 25, 2011Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Publication number: 20100184686Abstract: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to over-expression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule.Type: ApplicationFiled: January 19, 2010Publication date: July 22, 2010Applicant: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Publication number: 20100169992Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.Type: ApplicationFiled: November 2, 2007Publication date: July 1, 2010Inventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
-
Patent number: 7678372Abstract: The invention provides a method for the therapeutic treatment of a cancer in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 comprises at least one point mutation in the transmembrane domain of FGFR-4 that substitutes a hydrophilic amino acid for a hydrophobic amino acid. The method comprises administering to the mammal an effective amount of at least one inhibitor of the mutated FGFR-4.Type: GrantFiled: August 27, 2003Date of Patent: March 16, 2010Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Publication number: 20090123462Abstract: The present invention relates to the use of Fibroblast-Growth Factor Receptor (FGFR) agonists for the diagnosis, prevention and/or treatment of pathological conditions including, but not limited to hyperproliferative disorders, bone diseases and vascular diseases. Particularly, the use of FGFR-4 agonists, e.g. anti-FGFR-4 antibodies is described. Further, the invention relates to a pharmaceutical composition comprising the agonist as described above and a screening procedure.Type: ApplicationFiled: October 24, 2008Publication date: May 14, 2009Inventors: Johannes Bange, Axel Ullrich
-
Patent number: 7531304Abstract: The present invention relates to the use of Fibroblast-Growth Factor Receptor (FGFR) agonists for the diagnosis, prevention and/or treatment of pathological conditions including, but not limited to hyperproliferative disorders, bone diseases and vascular diseases. Particularly, the use of FGFR-4 agonists, e.g. anti-FGFR-4 antibodies is described. Further, the invention relates to a pharmaceutical composition comprising the agonist as described above and a screening procedure.Type: GrantFiled: January 30, 2003Date of Patent: May 12, 2009Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Johannes Bange, Axel Ullrich
-
Patent number: 7297774Abstract: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule.Type: GrantFiled: June 8, 2004Date of Patent: November 20, 2007Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Publication number: 20050153878Abstract: The present invention relates to the use of Fibroblast-Growth Factor Receptor (FGFR) agonists for the diagnosis, prevention and/or treatment of pathological conditions including, but not limited to hyperproliferative disorders, bone diseases and vascular diseases. Particularly, the use of FGFR-4 agonists, e.g. anti-FGFR-4 antibodies is described. Further, the invention relates to a pharmaceutical composition comprising the agonist as described above and a screening procedure.Type: ApplicationFiled: January 30, 2003Publication date: July 14, 2005Inventors: Johannes Bange, Axel Ullrich
-
Publication number: 20040235776Abstract: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule.Type: ApplicationFiled: June 8, 2004Publication date: November 25, 2004Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Patent number: 6770742Abstract: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule.Type: GrantFiled: September 7, 2000Date of Patent: August 3, 2004Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev
-
Publication number: 20040067885Abstract: The present invention concerns the use of inhibitors for the treatment and/or prophylaxis of diseases which are the consequence of increased receptor tyrosine kinase activity, particularly cancer. The use is particularly directed towards inhibition or lowering of the overexpression and/or altered activity of receptor tyrosine kinases (RTKs). In particular, this altered activity of receptor tyrosine kinase can be triggered by a mutation of FGFR-4, wherein this mutation is in particular a point mutation in the transmembrane domain of FGFR-4 and leads to an exchange of a hydrophobic amino acid for a hydrophilic amino acid. The invention further concerns the use of an inhibitor directed against FGFR-4, for the treatment and/or prophylaxis of cancer. Furthermore, the invention concerns a mutated FGFR-4, which leads to overexpression and/or altered activity in cells. Finally, the invention concerns a DNA and RNA sequence of a mutated FGFR-4 molecule.Type: ApplicationFiled: August 27, 2003Publication date: April 8, 2004Applicant: Max-Planck-Gesellschaft ZurInventors: Axel Ullrich, Johannes Bange, Pjotr Knyazev